

C.5	Deferasirox & deferoxamine – change representative medicine within square box listing – EML and EMLc
Draft recommendation	<input checked="" type="checkbox"/> Recommended <input type="checkbox"/> Not recommended <p>Justification: Deferasirox is an effective iron chelator for reduction of iron overload in patients. Following patent expiration, deferasirox has become more widely available globally from several manufacturers and its generic version is now a cost effective medicine.</p> <p>List the orally used iron chelator deferasirox as the main representative agent, while maintaining parenterally used deferoxamine as a therapeutic alternative to the EML.</p>
Does the proposed medicine address a relevant public health need?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>
Does adequate evidence exist for the efficacy/effectiveness of the medicine for the proposed indication? (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>
Does adequate evidence exist for the safety/harms associated with the proposed medicine? (this may be evidence included in the application, and/or additional evidence identified during the review process)	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>
Are there any adverse effects of concern, or that may require special monitoring?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable <p>Comments:</p>

24th WHO Expert Committee on Selection and Use of Essential Medicines
Expert review

<p>Are there any special requirements for the safe, effective and appropriate use of the medicines?</p> <p>(e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)</p>	<p><input checked="" type="checkbox"/> Yes</p> <p><input type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments: require monitoring tests for serum ferritin.</p>
<p>Are there any issues regarding cost, cost-effectiveness, affordability and/or access for the medicine in different settings?</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments: deferasirox show comparative cost effectiveness with deferoxamine in most setting.</p>
<p>Are there any issues regarding the registration of the medicine by national regulatory authorities?</p> <p>(e.g. accelerated approval, lack of regulatory approval, off-label indication)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>
<p>Is the proposed medicine recommended for use in a current WHO guideline?</p> <p>(refer to: https://www.who.int/publications/who-guidelines)</p>	<p><input type="checkbox"/> Yes</p> <p><input checked="" type="checkbox"/> No</p> <p><input type="checkbox"/> Not applicable</p> <p>Comments:</p>